Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Skyrizi Logo White

      Simplicity

      » Only 4 doses a year.*1

      *Following induction doses.

      decorative

      RELIABLE EVERY-12-WEEK MAINTENANCE DOSING.1†

      †Dose adjustment is not required regardless of patient subgroup.1-3

      SKYRIZI is dosed 150 mg at Week 0, Week 4, and every 12 weeks thereafter.

      dosage

      Clinically meaningful changes in efficacy and safety of SKYRIZI® were not observed with increased body weight, therefore no dose adjustment is necessary based on body weight.1

      decorative

      RAPID RESPONSE WITH NOTHING MORE THAN 2 DOSES.1,2,4-7*

      *Mean PASI improvement from baseline in PsO (UltIMMa-1 and 2 integrated analysis, LOCF)4 and ACR20 response over time in PsA6.

      Mean PASI improvement in PsO patients from baseline to:4

      WEEK 4

      58%#

      vs 9% placebo; P-value not reported

      WEEK 16

      91%#

      vs 10% placebo; P-value not reported

      WEEK 52

      95%#

      #Post-hoc integrated analysis (LOCF) from UltiMMa-1 and 2 where mean PASI improvement from baseline was calculated for SKYRIZI® (n=598) up to Week 52 and placebo (n=200) up to Week 16.4

      decorative

      ACR20 RESPONSE IN PsA PATIENTS OVER TIME6,7

      Percent patients who achieved ACR20:

      WEEK 4

      25.7%

      vs 13.7% placebo; nominal P≤0.001

      WEEK 16

      56.3%

      vs 33.4% placebo; P≤0.001

      WEEK 52

      70%

      Open-label extension; no statistical analyses performed.

      PBS Information

      SKYRIZI: Authority required for the treatment of adults with severe plaque psoriasis. SKYRIZI is not listed on the PBS for the treatment of psoriatic arthritis. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      SKYRIZI PI

      Abbreviations: ACR, American College of Rheumatology; LOCF, last observation carried forward; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; PsO, psoriasis.

      References: 1. SKYRIZI Approved Product Information. 2. Gordon KB et al. Lancet 2018;392(10148):650 -661. 3. Strober B et al. J Eur Acad Dermatol Venereol 2020;34(12):2830-2838. 4. Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: an integrated analysis of UltIMMa-1 and UltIMMa-2. Poster presented at: 2019 AAD Annual Meeting; March 1 -5, 2019; Washington, DC. Poster 8108. 5. Gordon KB et al. Lancet 2018;392(10148):650 -661 (Supplement). 6. Kristensen LE et al. Ann Rheum Dis 2022;81(2):225 -31. 7. Kristensen LE et al. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 1. Poster presented at the Fall Clinical Dermatology Conference (FC21), October 21 -24, 2021, Las Vegas, Nevada, Hybrid Meeting..

      AU-SKZD-210068. April 2024